Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910835 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Urmila Sehrawat. Beteiligte Einrichtung: Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Neoplasms, Protein Biosynthesis, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, MSK.
Abstract (Originalsprache)
Eukaryotic protein translation has slowly gained the scientific community’s attention for its advanced and powerful therapeutic potential. However, recent technical developments in studying ribosomes and global translation have revolutionized our understanding of this complex multistep process. These developments have improved and deepened the current knowledge of mRNA translation, sparking excitement and new possibilities in this field. Translation factors are crucial for maintaining protein synthesis homeostasis. Since actively proliferating cancer cells depend on protein synthesis, dysregulated protein translation is central to tumorigenesis. Translation factors and their abnormal expressions directly affect multiple oncogenes and tumor suppressors. Recently, small molecules have been used to target translation factors, resulting in translation inhibition in a gene-specific manner, opening the door for developing translation inhibitors that can lead to novel chemotherapeutic drugs for treating multiple cancer types caused by dysregulated translation machinery. This review comprehensively summarizes the involvement of translation factors in tumor progression and oncogenesis. Also, it sheds light on the evolution of translation factors as novel drug targets for developing future therapeutic drugs for treating cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
ORCID-Profile: Urmila Sehrawat
Förderung
- NCI NIH HHS
- MSK
Zitieren
APA
Sehrawat, U. (2024). Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910835
Vancouver
Sehrawat U. Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910835
BibTeX
@article{Sehrawat2024,
author = {Sehrawat, Urmila},
title = {Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910835}
}
EUVIMED